Key clinical highlights in HIV infection and COVID-19 are discussed in this interview with touchINFECTIOUS DISEASES Editorial Board member, Dr Nikolaus Jilg (Infectious Diseases Physician, Massachusetts General Hospital, Boston, MA, USA). Dr Jilg discusses the COVID-19 pandemic, the successful rollout of vaccines, the development of new treatments for COVID-19 and long-COVID, and markers of protection in future infections. He also discusses the progress in the development of HIV treatments in the past year, with the use of injectable HIV antiretrovirals coming to market, and further developments in HIV cure.
- What are the key clinical highlights from the past year in the field of infectious diseases? (0:16)
- What are the hot topics and latest research you are looking forward to exploring in 2022? (3:07)
Disclosures: Nikolaus Jilg receives salary support to his institution, Massachusetts General Hospital, by the AIDS Clinical Trials Group (ACTG) and Sagent Pharmaceuticals.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In HIV
Moti Ramgopal, IDWeek 2022: Unmet needs and challenges around maintenance of HIV-1 virologic suppression
In this touchINFECTIOUS DISEASES interview, we met with Dr Moti Ramgopal (Midway Research Center, FL, USA) to discuss the unmet needs and challenges around maintenance of HIV-1 virologic suppression. Dr Ramgopal discusses challenges around stigma, social issues, tolerability, injection site reactions, and patient satisfaction with their current treatment regimen. Access an interview with Dr Moti […]
Moti Ramgopal, IDWeek 2022: Phase 3/3b FLAIR and ATLAS-2M pooled analysis – Efficacy and safety outcomes through week 96 by race
Long-acting cabotegravir + rilpivirine administered monthly or every 2 months is the first and only complete long-acting regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression. In this touchINFECTIOUS DISEASES interview, we met with Prof. Moti Ramgopal (Midway Research Center, FL, USA) to discuss a post hoc analysis of pooled outcomes for […]
Marina Klein, AIDS2022: Global health burden and the elimination of HIV, hepatitis B, and hepatitis C
There are number of challenges in the elimination of the three blood-borne viruses — HIV, hepatitis B (HBV), and hepatitis C (HCV). Treatment advances have been made with the introduction of highly effective antiviral agents into clinical practice, and prevention strategies. However, for worldwide elimination of these viruses, effective vaccines are required. Dr Marina Klein […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!